Background: Large DNA poxviruses encode a diverse family of secreted proteins that modulate host inflammatory and antiviral responses, in particular by inhibiting one of the key players of the mammalian immune system, the tumor necrosis factor (TNF).
Methods: We investigated the effects of a recombinant variola (smallpox) virus TNF-decoy receptor (VARV-CrmB) in a murine model of contact dermatitis. Our results demonstrate that the VARV-CrmB protein significantly reduces the 2,4-dinitrochlorbenzene (DNCB)-induced migration of skin leukocytes during the sensitization phase and suppresses ear oedema during the elicitation phase of the contact reaction.
Results: Studies focusing on the bone marrow hematopoiesis in the contact dermatitis model revealed that the epicutaneous co-application of DNCB and VARV-CrmB protein normalized the DNCB-induced effects to control levels.
Conclusion: As an effective TNF antagonist, the VARV-CrmB protein might be conceived as a beneficial candidate for further research and development of therapeutic approaches in the field of the inflammatory skin diseases.
|Number of pages||7|
|Journal||Current Pharmaceutical Biotechnology|
|Publication status||Published - 1 Jan 2019|
- Bone marrow
- cell migration
- contact dermatitis
- human TNF (hTNF)
- murine TNF (muTNF)
- TNF-decoy receptor
- variola virus
- LANGERHANS CELL-MIGRATION
- BINDING PROTEINS
- Variola virus
- TNFdecoy receptor
- Human TNF (hTNF)
- Murine TNF (muTNF)
- Contact dermatitis
- Cell migration
- Tumor Necrosis Factor Decoy Receptors/isolation & purification
- Viral Proteins/administration & dosage
- Tumor Necrosis Factor-alpha/antagonists & inhibitors
- Anti-Inflammatory Agents/isolation & purification
- Disease Models, Animal
- Receptors, Tumor Necrosis Factor/administration & dosage
- Mice, Inbred BALB C
- Dermatitis, Allergic Contact/drug therapy